Discover

ELDN
Eledon Pharmaceuticals, Inc.
3.69
7 x 3.65
30 x 3.79
bid
ask
+
0.23
6.65%
1 @ 04:00 PM
3.78 +0.09 (2.49%)
Ytd144.37%
1y34.67%
3.51
day range
3.70
1.39
52 week range
4.36
Open3.51Prev Close3.46Low3.51High3.70Mkt Cap284.82M
Vol925.41KAvg Vol1.35MEPS-0.77P/E-4.79Forward P/E-3.49
Beta0.98Short Ratio0.75Inst. Own42.88%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg3.75200-d Avg2.901yr Est12.50

ELDN News

Eledon: At The Center Of The Next Medical Frontier
seekingalpha.com
Eledon: At The Center Of The Next Medical Frontier

Eledon Pharmaceuticals (ELDN) is rated Buy, with tegoprubart showing strong promise post-Phase 2 in

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
benzinga.com
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
businesswire.com
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cel

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
seekingalpha.com
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Tr

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Tr

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
globenewswire.com
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing S

Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
zacks.com
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
globenewswire.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in P

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
globenewswire.com
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of

IRVINE, Calif. , June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq:

Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
zacks.com
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?

Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to t

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
globenewswire.com
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for th

IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: EL

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart foll

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
globenewswire.com
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strat

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),- NewcelX Ltd. (

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages
defenseworld.net
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have been given an average r

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
globenewswire.com
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following is

Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative
seekingalpha.com
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative

Eledon Pharmaceuticals remains a "Strong Buy" following positive phase 2 BESTOW results for tegoprub

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
globenewswire.com
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention o

IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
prnewswire.com
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program fo

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerlan

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq:

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: E

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

benzinga.com
Earnings Scheduled For March 30, 2023

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 479 stocks made new 52-week lows.